Abstract
Aim: The study was conducted to evaluate the effects of Ginkgo biloba as an add on therapy to Valsartan monotherapy in hypertensive patients on lipid profile.
Patients and methods: The study was done in private clinics in Mosul City, during a period of sixth months from 15 October 2017 to 15 April 2018. The total number of patients enrolled in the study was 50 hypertensive patients using Valsartan monotherapy of both sexes. The patients were administered Ginkgo biloba 80 mg twice daily and followed for 2 months duration. Their lipid profile was determined at baseline level and after 2 months from administration of Ginkgo biloba.
Results: Treatment with Ginkgo biloba showed a significant reduction in serum total cholesterol and triglycerides, while LDL, VLDL, HDL, and AI showed no significant changes.
Conclusion: This study revealed that Ginkgo biloba could be regarded as a natural and relatively safe drug in reducing total cholesterol and triglycerides in hypertensive patients.
.
